Related Experiment Video
Updated: Feb 26, 2026
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
Published on: March 7, 2025
Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities
Nirmala Chandralega Kampan1,2,3, Sue D Xiang1,4, Orla M McNally2
1Department of Immunology & Pathology, Monash University, Level 6, The Alfred, Commercial Road, Melbourne 3181, VIC, Australia.
Abstract:
Interleukin 6 (IL-6), a well-known pro-inflammatory cytokine with pleiotropic activity is a central player in chronic inflammatory diseases including cancers. Therefore, blockade of the IL-6 signalling pathway has become a target for the therapy of diverse cancers such as multicentric Castleman's disease (CD), multiple myeloma and solid tumours including renal, prostate, lung, colorectal and ovarian cancers. Monoclonal antibodies against IL-6 (Siltuximab) and the IL-6 receptor (IL-6R) (Tocilizumab) have emerged as potential immunotherapies, alone or in combination with conventional chemotherapy. Human trials have demonstrated the ability to block IL-6 activity and in multicentric CD lead to durable clinical response and longer disease stabilisation. However, the efficacy of these treatments is still debatable for other cancers. New generation therapeutics in development such as Clazakizumab, Sarilumab, and soluble gp130-Fc have the additional features of improved binding affinity, better specificity with reduced adverse effects. A deeper understanding of the immunological basis of these agents, as well as of the challenges that are faced by immunotherapy-based products in clinical trials, will help select the most promising anti-IL-6/IL-6R therapies for large scale use. Concurrently, current research efforts to personalize treatments may help in the treatment of patients that would greatly benefit from IL-6 blocking therapies.
Insights
Interleukin 6 (IL-6) blockade shows promise in treating cancers like multicentric Castleman
Area of Science:
- Immunology and Cancer Therapy
Background:
- Interleukin 6 (IL-6) is a pro-inflammatory cytokine central to chronic inflammatory diseases and various cancers.
- Targeting the IL-6 signaling pathway is a therapeutic strategy for multiple myeloma, multicentric Castleman's disease (CD), and solid tumors.
Purpose of the Study:
- To review the therapeutic potential of blocking Interleukin 6 (IL-6) and its receptor (IL-6R) in cancer treatment.
- To discuss current and emerging anti-IL-6/IL-6R therapies and their clinical trial challenges.
Main Methods:
- Review of existing literature on IL-6, IL-6R, and their role in cancer.
- Analysis of clinical trial data for IL-6/IL-6R blocking agents like Siltuximab and Tocilizumab.
- Discussion of next-generation therapeutics including Clazakizumab, Sarilumab, and soluble gp130-Fc.
Main Results:
- Monoclonal antibodies against IL-6 (Siltuximab) and IL-6R (Tocilizumab) demonstrate efficacy in blocking IL-6 activity.
- These therapies have shown durable clinical response and disease stabilization in multicentric Castleman's disease.
- Efficacy in other cancers remains under investigation, with new agents offering improved affinity and specificity.
Conclusions:
- Understanding the immunological basis of anti-IL-6/IL-6R agents is crucial for selecting effective therapies.
- Personalized treatment approaches may enhance the benefits of IL-6 blocking therapies for specific patient populations.
- Further research is needed to overcome challenges in clinical trials and optimize immunotherapy for cancer treatment.
More Related Videos
11:08Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:17The Tumor Microenvironment
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...